Literature DB >> 19053759

Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Cyril Barinka1, Youngjoo Byun, Crystal L Dusich, Sangeeta R Banerjee, Ying Chen, Mark Castanares, Alan P Kozikowski, Ronnie C Mease, Martin G Pomper, Jacek Lubkowski.   

Abstract

Urea-based, low molecular weight ligands of glutamate carboxypeptidase II (GCPII) have demonstrated efficacy in various models of neurological disorders and can serve as imaging agents for prostate cancer. To enhance further development of such compounds, we determined X-ray structures of four complexes between human GCPII and urea-based inhibitors at high resolution. All ligands demonstrate an invariant glutarate moiety within the S1' pocket of the enzyme. The ureido linkage between P1 and P1' inhibitor sites interacts with the active-site Zn(1)(2+) ion and the side chains of Tyr552 and His553. Interactions within the S1 pocket are defined primarily by a network of hydrogen bonds between the P1 carboxylate group of the inhibitors and the side chains of Arg534, Arg536, and Asn519. Importantly, we have identified a hydrophobic pocket accessory to the S1 site that can be exploited for structure-based design of novel GCPII inhibitors with increased lipophilicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19053759      PMCID: PMC5516903          DOI: 10.1021/jm800765e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

1.  A metabolically stable tight-binding transition-state inhibitor of glyoxalase-I.

Authors:  Swati S More; Robert Vince
Journal:  Bioorg Med Chem Lett       Date:  2006-09-25       Impact factor: 2.823

2.  NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats.

Authors:  Chunlong Zhong; Xueren Zhao; Jayaprakash Sarva; Alan Kozikowski; Joseph H Neale; Bruce G Lyeth
Journal:  J Neurotrauma       Date:  2005-02       Impact factor: 5.269

3.  Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography.

Authors:  Tomás R Guilarte; Jennifer L McGlothan; Catherine A Foss; Jia Zhou; Warren D Heston; Alan P Kozikowski; Martin G Pomper
Journal:  Neurosci Lett       Date:  2005-10-28       Impact factor: 3.046

4.  Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.

Authors:  Y Kinoshita; K Kuratsukuri; N Newman; P M Rovito; P T P Kaumaya; C Y Wang; G P Haas
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

5.  Expression of glutamate carboxypeptidase II in human brain.

Authors:  P Sácha; J Zámecník; C Barinka; K Hlouchová; A Vícha; P Mlcochová; I Hilgert; T Eckschlager; J Konvalinka
Journal:  Neuroscience       Date:  2006-12-05       Impact factor: 3.590

6.  Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates.

Authors:  Jack Maung; Jeremy P Mallari; Teri A Girtsman; Lisa Y Wu; Jennifer A Rowley; Nicholas M Santiago; Alan N Brunelle; Clifford E Berkman
Journal:  Bioorg Med Chem       Date:  2004-09-15       Impact factor: 3.641

7.  Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs.

Authors:  Cyril Barinka; Klara Hlouchova; Miroslava Rovenska; Pavel Majer; Miroslawa Dauter; Niyada Hin; Yao-Sen Ko; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2008-01-05       Impact factor: 5.469

8.  Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.

Authors:  Cyril Barinka; Miroslava Rovenská; Petra Mlcochová; Klára Hlouchová; Anna Plechanovová; Pavel Majer; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Med Chem       Date:  2007-06-14       Impact factor: 7.446

9.  Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase.

Authors:  P F Jackson; D C Cole; B S Slusher; S L Stetz; L E Ross; B A Donzanti; D A Trainor
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

10.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

View more
  45 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Authors:  Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel
Journal:  J Am Chem Soc       Date:  2010-09-15       Impact factor: 15.419

4.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

5.  Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study.

Authors:  Michael A Gorin; Steven P Rowe; Hiten D Patel; Igor Vidal; Margarita Mana-Ay; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Edward M Schaeffer; Trinity J Bivalacqua; Alan W Partin; Kenneth J Pienta; Zsolt Szabo; Angelo M De Marzo; Martin G Pomper; Mohamad E Allaf
Journal:  J Urol       Date:  2017-07-20       Impact factor: 7.450

Review 6.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

7.  Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.

Authors:  Samuel R Denmeade; Annastasiah M Mhaka; D Marc Rosen; W Nathaniel Brennen; Susan Dalrymple; Ingrid Dach; Claus Olesen; Bora Gurel; Angelo M Demarzo; George Wilding; Michael A Carducci; Craig A Dionne; Jesper V Møller; Poul Nissen; S Brøgger Christensen; John T Isaacs
Journal:  Sci Transl Med       Date:  2012-06-27       Impact factor: 17.956

Review 8.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

9.  [(18)F]Fluoroethyl Triazole Substituted PSMA Inhibitor Exhibiting Rapid Normal Organ Clearance.

Authors:  Ying Chen; Ala Lisok; Samit Chatterjee; Bryan Wharram; Mrudula Pullambhatla; Yuchuan Wang; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Bioconjug Chem       Date:  2016-06-24       Impact factor: 4.774

10.  Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.

Authors:  Ryan P Murelli; Andrew X Zhang; Julien Michel; William L Jorgensen; David A Spiegel
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.